✦ LIBER ✦

Phase I study of high-dose cytosine arabinoside and etoposide in patients with advanced malignancies

✍ Scribed by Bayard L. Powell; Hyman B. Muss; Robert L. Capizzi; Mary E. Caponera; Douglas R. White; Patricia J. Zekan; James N. Atkins; Don V. Jackson; Frederick Richards; John B. Craig; Julia M. Cruz; Charles L. Spurr

Publisher: Springer
Year: 1987
Tongue: English
Weight: 273 KB
Volume: 19
Category: Article
ISSN: 0344-5704
DOI: 10.1007/bf00252981

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Prolonged administration of low dose inf

Prolonged administration of low dose infusional etoposide in patients with advanced malignancies. A phase I/II study

✍ Dana S. Thompson; John D. Hainsworth; Kenneth R. Hande; Mary Holzmer; F. Anthony 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 738 KB

## Background: Etoposide displays remarkable schedule dependency. to better define the optimal dose and schedule, the authors administered etoposide as a prolonged low daily dose infusion in patients with a variety of advanced malignancies. ## Methods: Between october 1989 and april 1992, 40 pati

Phase I study of high dose 5-fluorouraci

Phase I study of high dose 5-fluorouracil and high dose leucovorin with low dose phosphonacetyl-l-aspartic acid in patients with advanced malignancies

✍ Bach Ardalan; Kasi Stridhar; Rajender Reddy; Pasquale Benedetto; Stephen Richman 📂 Article 📅 1992 🏛 Elsevier Science 🌐 English ⚖ 416 KB

Phase I–II study of high-dose etoposide

Phase I–II study of high-dose etoposide in patients with refractory breast cancer

✍ Giuseppe Fraschini; Frankie A. Holmes; Laura Esparza; Richard L. Theriault; Aman 📂 Article 📅 1991 🏛 Springer US 🌐 English ⚖ 162 KB

A phase I, II study of high-dose 5-fluor

A phase I, II study of high-dose 5-fluorouracil and high-dose leucovorin with low-dose phosphonacetyl-L-aspartic acid in patients with advanced malignancies

✍ Bach Ardalan; Kasi S. Sridhar; Pasquale Benedetto; Stephen Richman; Stuart Waldm 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 454 KB 👁 3 views

Phase I dose and sequencing study of peg

Phase I dose and sequencing study of pegylated liposomal doxorubicin and docetaxel in patients with advanced malignancies

✍ Paula M. Fracasso; Luis C. Rodriguez; Thomas J. Herzog; Carole L. Fears; Sherry 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 89 KB 👁 1 views

## Abstract ## BACKGROUND Pegylated liposomal doxorubicin (PEG‐LD) and docetaxel have single‐agent activity in several malignancies. The authors conducted a Phase I trial to evaluate the maximum tolerated dose (MTD), toxicities, and effect of dose sequencing of this combination in patients with ad

Phase I study of pegylated liposomal dox

Phase I study of pegylated liposomal doxorubicin and gemcitabine in patients with advanced malignancies

✍ Paula M. Fracasso; Kristie A. Blum; Benjamin R. Tan; Carole L. Fears; Nancy L. B 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 71 KB 👁 2 views

## Abstract ## BACKGROUND Pegylated liposomal doxorubicin (PEG‐LD) and gemcitabine have single‐agent activity in breast and ovarian carcinoma patients. We conducted a Phase I trial to evaluate the maximum tolerated dose (MTD) and toxicities of this combination in patients with advanced malignancie